Roche’s Genentech has entered into a novel collaboration with Forma Therapeutics. Under the terms of the agreement, Genentech will receive exclusive worldwide rights to acquire a preclinical cancer programme from Forma at a defined future phase of development. In return, Forma will receive an undisclosed upfront payment, research funding and potential development milestone payments. If Genentech exercises its option, Forma will receive a significant buyout payment, thus providing a relatively early return for its investors.